CV (CapsoVision) ROE % Adjusted to Book Value: -9.36% (As of Mar. 2026)


CV CapsoVision Inc CV
10 GF Score
Price $6.99
! 1 Warning Sign
View Full Analysis

What is CapsoVision ROE % Adjusted to Book Value?

CapsoVision CV -1.69% 10 ROE % Adjusted to Book Value is -9.36% as of Mar. 2026. GuruFocus rates CV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

CapsoVision's ROE % for the quarter that ended in Mar. 2026 was -168.05%. CapsoVision's PB Ratio for the quarter that ended in Mar. 2026 was 17.96. CapsoVision's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -9.36%.

CapsoVision ROE % Adjusted to Book Value Related Terms

CapsoVision ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for CapsoVision's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CapsoVision ROE % Adjusted to Book Value Chart

CapsoVision Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00

CapsoVision Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -4.65 -9.36

CV vs SENS, MASS, ELMD: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, CapsoVision's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CapsoVision ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CapsoVision's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CapsoVision's ROE % Adjusted to Book Value falls into.


CV
10GF Score
CapsoVision Inc CV
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CapsoVision ROE % Adjusted to Book Value Calculation

CapsoVision's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 37.77
=0.00%

CapsoVision's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-168.05% / 17.96
=-9.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.36% mean?
CapsoVision (CV) has a ROE % Adjusted to Book Value of -9.36% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CapsoVision and its competitors.
Is CapsoVision's ROE % Adjusted to Book Value too high?
CapsoVision's current ROE % Adjusted to Book Value is -9.36%. Overall, CapsoVision has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's ROE % Adjusted to Book Value compare to SENS and MASS?
CapsoVision's ROE % Adjusted to Book Value of -9.36% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CapsoVision and its competitors. CapsoVision's current ROE % Adjusted to Book Value is -9.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current ROE % Adjusted to Book Value of -9.36%. The current ROE % Adjusted to Book Value is -9.36%. CapsoVision's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For CapsoVision (CV), the current ROE % Adjusted to Book Value is -9.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CapsoVision Business Description

Other Exchanges H6U:Germany
Address 18805 Cox Avenue, Suite 250, Saratoga, CA, USA, 95070
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
10GF Score

Get the complete analysis for CV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price